| Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. | |
| | |
MedLine Citation:
|
PMID: 18294563 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Atrial fibrillation (AF) is the most common arrhythmia in the clinical setting, and traditional pharmacological approaches have proved to have important weaknesses. Structural remodeling has been observed in both clinical and experimental AF paradigms, and is an important feature of the AF substrate, producing fibrosis that alters atrial tissue composition and function. The precise mechanisms underlying atrial fibrosis are not fully elucidated, but recent experimental studies and clinical investigations have provided valuable insights. A variety of signaling systems, particularly involving angiotensin II and related mediators, seem to be centrally involved in the promotion of fibrosis. This paper reviews the current understanding of how atrial fibrosis creates a substrate for AF, summarizes what is known about the mechanisms underlying fibrosis and its progression, and highlights emerging therapeutic approaches aimed at attenuating structural remodeling to prevent AF. |
| | |
Authors:
|
Brett Burstein; Stanley Nattel |
Related Documents
:
|
17302693 - Left atrial remodeling: assessment of size and shape to detect vulnerability to atrial ... 17261703 - Left atrial appendage exclusion for stroke prevention in patients with nonrheumatic atr... 22736093 - How early in the course of rheumatoid arthritis does the excess cardiovascular risk app... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Journal of the American College of Cardiology Volume: 51 ISSN: 1558-3597 ISO Abbreviation: J. Am. Coll. Cardiol. Publication Date: 2008 Feb |
Date Detail:
|
Created Date: 2008-02-25 Completed Date: 2008-03-06 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8301365 Medline TA: J Am Coll Cardiol Country: United States |
Other Details:
|
Languages: eng Pagination: 802-9 Citation Subset: AIM; IM |
Affiliation:
|
Research Center and Department of Medicine, Montreal Heart Institute and Université de Montréal, and Department of Pharmacology and Therapeutics, McGill University, Montreal, Quebec, Canada. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Anti-Arrhythmia Agents / pharmacology, therapeutic use Atrial Fibrillation / drug therapy, etiology*, pathology* Fibrosis Heart Atria / drug effects, pathology* Humans |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Arrhythmia Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Mechanisms, prevention, and treatment of atrial fibrillation after cardiac surgery.
Next Document: Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atri...